Esketamine nasal spray vs aripiprazole for depression in older adults
Part of Mental health clinical trials.
This study tests whether a nasal spray (esketamine) is more effective than aripiprazole (an oral medication) for treating depression in adults aged 60-74 who haven't responded to at least three previous antidepressants. The goal is to see which option helps better when standard treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 74 years old.
- You have major depression that hasn't improved enough after trying at least three different antidepressants (each taken for at least 6 weeks at a proper dose).
- You are currently taking one antidepressant and it's not working well (less than 25% improvement after at least 6 weeks).
- You are not at high risk of suicide (based on a standard evaluation).
- You do not have any medical condition that makes it unsafe to use esketamine or aripiprazole, such as certain blood pressure or brain pressure issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses brain scans to understand how ketamine affects negative emotions in people with depression. It may help explain why ketamine works and who benefits most.
This study tests a new experimental drug (2R,6R)-HNK, a chemical related to ketamine, given by IV infusion to see if it can help people with depression that hasn't improved with other treatments. The goal is to find a new option for people who have not found relief from standard antidepressants.
This study tests esketamine nasal spray versus a placebo in adults with depression that has not improved after trying at least two other antidepressants. It aims to see if the spray can help when standard pills have not worked.
This study tests whether esketamine, a nasal spray for depression, can help adults whose depression has not improved with at least two other antidepressants. Participants continue their current treatment while receiving esketamine.
This study tests esketamine nasal spray (a fast-acting antidepressant) for people with treatment-resistant depression who haven't gotten better after trying at least two other antidepressants. It looks at how well the spray works in everyday doctor's offices, not just in research clinics.
This study compares the effectiveness of esketamine (Spravato) and another similar drug, ketamine, for adults with major depression that has not improved after trying at least two other antidepressants. It aims to find out which treatment works better.
Hear when a new Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.